FDA approval of the Alzheimer's drug could positively incentivize further market innovation, despite the modest initial results.

“they may be taking a long-term view and what they could be really doing is creating a market that ultimately incentivizes other folks to come in where then ultimately those people are the ones that find the solution, right?”

The Biogen drug's approval is problematic because it demonstrated low efficacy while carrying a high price tag.

“So, that's problem one in the pharmaceutical kind of debate is should we be charging the you know, the quality of life premium? And then number two Yeah, it and then part you know, the kind of second issue is like should this thing have been approved when it wasn't really that efficacious”

Regulators should allow the drug to be used for terminal patients and observe its performance before deciding on revocation.

“These people have nothing to lose and so, I would let the drug through, I think, and then watch how it performs over the next couple of years. They could always revoke the approval in 2 years.”